Intragraft regulatory T cells in protocol biopsies retain Foxp3 demethylation and are protective biomarkers for kidney graft outcome

American Journal of Transplantation

Volumn 11, Issue 10, 2011, Pages 2162-2172

  Bestard, O ^a   Cunetti L ^a,c   Cruzado, J M ^a   Lucia, M ^a   Valdez, R ^a   Olek, S ^b   Melilli, E ^a   Torras, J ^a   Mast, R ^a   Goma M ^a   Franquesa, M ^a   Grinyo J M ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b EPIONTIS GMBH   (Germany)

^c UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

Author keywords

Foxp3+ T reg; protocol biopsies; renal transplantation; subclinical rejection

Indexed keywords

BASILIXIMAB; BIOLOGICAL MARKER; CALCINEURIN INHIBITOR; RAPAMYCIN; THYMOCYTE ANTIBODY; TRANSCRIPTION FACTOR FOXP3;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CD3+ T LYMPHOCYTE; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DEMETHYLATION; DNA METHYLATION; FEMALE; GRAFT FAILURE; GRAFT REJECTION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TUBULE ATROPHY; KIDNEY TUBULE DAMAGE; LYMPHOCYTIC INFILTRATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SUBCLINICAL REJECTION; TREATMENT OUTCOME;

ADULT; BIOLOGICAL MARKERS; BIOPSY; CASE-CONTROL STUDIES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; METHYLATION; MIDDLE AGED; RETROSPECTIVE STUDIES; T-LYMPHOCYTES, REGULATORY;

EID: 80053295173     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03633.x     Document Type: Article

References (33)

1. Hori S, Nomura T, Sakaguchi S,. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-1061. (Pubitemid 36222930)
2. Marson A, Kretschmer K, Frampton GM, et al., Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 2007; 445: 931-935.
3. Bennett CL, Christie J, Ramsdell F, et al., The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001; 27: 20-21. (Pubitemid 32044513)
4. Ochando JC, Homma C, Yang Y, et al., Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol 2006; 7: 652-662. (Pubitemid 43797347)
5. Lee I, Wang L, Wells AD, et al., Recruitment of FoxP3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. J Exp Med 2005; 201: 1037-1044. (Pubitemid 40524671)
6. Bestard O, Cruzado JM, Mestre M, et al., Achieving donor-specific hyporesponsiveness is associated with FOXP3+ regulatory T cell recruitment in human renal allograft infiltrates. J Immunol 2007; 179: 4901-4909.
7. Noris M, Casiraghi F, Todeschini M, et al., Regulatory T cells and T cell depletion: Role of immunosuppressive drugs. J Am Soc Nephrol 2007; 18: 1007-1018. (Pubitemid 46434518)
8. Shinkura R, Kitada K, Matsuda F, et al., Alymphoplasia is caused by a point mutation in the mouse gene encoding Nf-kappa b-inducing kinase. Nat Genet 1999; 22: 74-77. (Pubitemid 29214808)
9. Lakkis FG, Arakelov A, Konieczny BT, Inoue Y,. Immunologic 'ignorance' of vascularized organ transplants in the absence of secondary lymphoid tissue. Nat Med 2000; 6: 686-688. (Pubitemid 30398793)
10. Zhou P, Hwang KW, Palucki D, et al., Secondary lymphoid organs are important but not absolutely required for allograft responses. Am J Transplant 2003; 3: 259-266. (Pubitemid 36407042)
11. Graca L, Cobbold SP, Waldmann H,. Identification of regulatory T cells in tolerated allografts. J Exp Med 2002; 195: 1641-1646. (Pubitemid 34666077)
12. Brown K, Moxham V, Karegli J, Phillips R, Sacks SH, Wong W,. Ultra-localization of Foxp3+ T cells within renal allografts shows infiltration of tubules mimicking rejection. Am J Pathol 2007; 171: 1915-1922.
13. Zhigang F, Spencer JA, Yan L, et al., In vivo tracking of "color-coded" effector, natural and induced regulatory t cells in the allograft response. Nat Med 2010; 16: 718-722.
14. Bestard O, Cruzado JM, Rama I, et al., Presence of FoxP3+ regulatory T cells predicts outcome of subclinical rejection of renal allografts. J Am Soc Nephrol 2008; 19: 2020-2026.
15. Grimbert P, Mansour H, Desvaux D, et al., The regulatory/cytotoxic graft-infiltrating T cells differentiate renal allograft borderline change from acute rejection. Transplantation 2007; 83: 341-346.
16. Mansour H, Homs S, Desvaux D, et al., Intragraft levels of Foxp3 mRNA predict progression in renal transplants with borderline change. J Am Soc Nephrol 2008; 19: 2277-2281.
17. Veronesse F, Rotman S, Smith RN, et al., Pathological and clinical correlates of FoxP3+ cells in renal allografts during acute rejection. Am J Transplant 2007; 7: 914-922. (Pubitemid 46481190)
18. Bunnag S, Allanach K, Jhangri GS, et al., FOXP3 expression in human kidney transplant biopsies is associated with rejection and time post transplant but not with favorable outcomes. Am J Transplant 2008; 8: 1423-1433. (Pubitemid 351989494)
19. Ziegler SF,. FOXP3: Not just for regulatory T cells anymore. Eur J Immunol 2007; 37: 21-23. (Pubitemid 46128782)
20. Walker MR, Ka sprowicz DJ, Gersuk VH, et al., Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25+ T cells. J Clin Invest 2003; 112: 1437-1443. (Pubitemid 38057697)
21. Roncador G, Brown PJ, Maestre L, et al., Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur J Immunol 2005; 35: 1681-1691. (Pubitemid 40862316)
22. Baron U, Floess S, Wieczorek G, et al., DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. Eur J Immunol 2007; 37: 2378-2389. (Pubitemid 47423608)
23. Sehouli J, Loddenkemper C, Cornu T, et al., Epigenetic quantification of tumor-infiltrating T-lymphocytes. Epigenetics 2011; 6: 236-246.
24. Moreso F, Ibernon M, Gomà M, et al., Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant 2006; 6: 747-750.
25. Cosio FG, grande JP, Wadei H, et al., Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005; 5: 1130-1136.
26. Sis B, Mengel M, Haas M, et al., Banff '09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464-471.
27. Wieczorek G, Asemissen A, Model F, et al., Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res 2009; 69: 599-560.
28. Koulmanda M, Budo E, Bonner-Weir S, et al., Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts. Proc Natl Acad Sci U S A 2007; 104: 13074-13079. (Pubitemid 351737595)
29. Lal G, Zhang N, Van Der Touw W, et al., Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol 2009; 182: 259-273.
30. Sewgobind VD, van der Laan LJ, Kho MM, et al., The calcineurin inhibitor tacrolimus allows the induction of functional CD4CD25 regulatory T cells by rabbit anti-thymocyte globulins. Clin Exp Immunol 2010; 161: 364-377.
31. Velthuis JH, Hesselink DA, Hendrikx TK, et al., Kinetic analysis reveals potency of CD4+ CD25bright+ regulatory T-cells in kidney transplant patients. Transpl Immunol 2007; 18: 159-165. (Pubitemid 350086961)
32. Taflin C, Nochy D, Hill G, et al., Regulatory T cells in kidney allograft infiltrates correlate with initial inflammation and graft function. Transplantation 2010; 89: 194-199.
33. Zuber J, Brodin-Sartorius A, Lapidus N, et al., FOXP3-enriched infiltrates associated with better outcome in renal allografts with inflamed fibrosis. Nephrol Dial Transplant 2009; 24: 3847-3854.